Summary
1.16 0.02(1.31%)05/17/2024
Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics Inc. (AKBA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -6.04 | 11.11 | -8.50 | -15.15 | 28.44 | 32.08 | -76.94 | -94.76 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.40 | |
| Open | 1.51 | |
| High | 1.56 | |
| Low | 1.38 | |
| Volume | 4,088,622 | |
| Change | -0.09 | |
| Change % | -6.04 | |
| Avg Volume (20 Days) | 2,728,808 | |
| Volume/Avg Volume (20 Days) Ratio | 1.50 | |
| 52 Week Range | 0.78 - 2.48 | |
| Price vs 52 Week High | -43.55% | |
| Price vs 52 Week Low | 79.49% | |
| Range | -7.28 | |
| Gap Up/Down | 0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 241 | |
| EBIDTA | -6,868,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 5.00 | |
| Book Value | -0.1570 | |
| Earnings Per Share | -0.2800 | |
| EPS Estimate Current Quarter | -0.0800 | |
| EPS Estimate Next Quarter | -0.0600 | |
| EPS Estimate Current Year | -0.2900 | |
| EPS Estimate Next Year | -0.3200 | |
| Diluted EPS (TTM) | -0.2800 | |
| Revenues | ||
| Profit Marging | -0.2668 | |
| Operating Marging (TTM) | 0.0526 | |
| Return on asset (TTM) | -0.0931 | |
| Return on equity (TTM) | -5.5345 | |
| Revenue TTM | 194,623,008 | |
| Revenue per share TTM | 1.0380 | |
| Quarterly Revenue Growth (YOY) | 0.0070 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 140,039,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.1167 | |
| Revenue Enterprise Value | 1.5973 | |
| EBITDA Enterprise Value | -76.8173 | |
| Shares | ||
| Shares Outstanding | 209,595,008 | |
| Shares Float | 190,197,962 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.07 | |
| Insider (%) | 1.93 | |
| Institutions (%) | 26.41 | |
05/14 08:00 EST - prnewswire.com
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20 th, 2024 at 3:00 p.m.
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20 th, 2024 at 3:00 p.m.
05/09 10:54 EST - seekingalpha.com
Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Corporate Communications and IR John Butler - President and Chief Executive Officer Nicholas Grund - Chief Commercial Officer Conference Call Participants Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Hello, and welcome to the Akebia's First Quarter 2024 Financial Results Conference Call.
Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Corporate Communications and IR John Butler - President and Chief Executive Officer Nicholas Grund - Chief Commercial Officer Conference Call Participants Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Hello, and welcome to the Akebia's First Quarter 2024 Financial Results Conference Call.
05/09 09:10 EST - zacks.com
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
05/09 07:00 EST - prnewswire.com
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Akebia to host conference call at 8:00 a.m. ET on May 9 Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 Vafseo launch activities underway with availability expected in January 2025 Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, Akebia expects 2024 Auryxia net product revenue growth versus 2023 CAMBRIDGE, Mass.
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Akebia to host conference call at 8:00 a.m. ET on May 9 Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 Vafseo launch activities underway with availability expected in January 2025 Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, Akebia expects 2024 Auryxia net product revenue growth versus 2023 CAMBRIDGE, Mass.
05/02 08:30 EST - prnewswire.com
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.
05/01 16:05 EST - prnewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , May 1, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 41,000 shares of Akebia's common stock on April 30, 2024, as inducements material to such employee entering into employment with Akebia.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , May 1, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 41,000 shares of Akebia's common stock on April 30, 2024, as inducements material to such employee entering into employment with Akebia.
04/04 17:56 EST - seekingalpha.com
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis, offering improved anemia management for a large patient population. The company's other FDA-approved drug, Auryxia, will face generic competition after its patent exclusivity expires in March 2025. Akebia is also working on a pipeline of acute care drugs expected to enter clinical trials in 2025, while Vafseo is expected to become the company's main revenue driver.
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis, offering improved anemia management for a large patient population. The company's other FDA-approved drug, Auryxia, will face generic competition after its patent exclusivity expires in March 2025. Akebia is also working on a pipeline of acute care drugs expected to enter clinical trials in 2025, while Vafseo is expected to become the company's main revenue driver.
04/03 09:11 EST - marketbeat.com
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.
03/28 08:11 EST - zacks.com
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
03/27 20:45 EST - reuters.com
U.S. FDA approves Akebia's anemia drug
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.
U.S. FDA approves Akebia's anemia drug
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.
03/27 20:26 EST - prnewswire.com
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass. , March 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass. , March 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
03/14 18:31 EST - zacks.com
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.
03/14 16:15 EST - prnewswire.com
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferric citrate) net product revenue of $170.3 million CAMBRIDGE, Mass. , March 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2023 and recent business highlights.
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferric citrate) net product revenue of $170.3 million CAMBRIDGE, Mass. , March 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2023 and recent business highlights.
03/11 17:05 EST - prnewswire.com
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.
01/30 08:00 EST - prnewswire.com
Akebia Secures $55 Million Term Loan Financing
Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass. , Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock.
Akebia Secures $55 Million Term Loan Financing
Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass. , Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock.
01/09 08:30 EST - prnewswire.com
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer.
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer.